Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve

• Status: Not yet recruiting
• Trial end date: 2023-04-14
• Target enrollment: 0
• Participant gender: Female

Summary

This study aimed to compare the gonadotropin-releasing hormone agonist (ultra-short) protocol versus (short and long) protocols on ovarian reserve in women undergoing intracytoplasmic sperm injection

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Hormones

Criteria

Inclusion Criteria:

• women

• aged between 18- and 35-years old

• undergoing Intracytoplasmic sperm injection.

Exclusion Criteria:

• History of three or more previous In vitro fertilisation failures

• Karyotypic abnormalities in either partner

• Patients who previously undergo unilateral oophorectomy

• Patients with chronic diseases (uncontrolled diabetes mellitus, cardiovascular diseases, liver and kidney failure)

• Patients with diseases may affect In vitro fertilisation outcomes (Endometriosis, uterine fibroids, Hydrosalpinx, Adenomyosis, autoimmune diseases), polycystic ovary syndrome (PCOS) patients, poor responders (maternal age >40, Antral follicle counts (AFC)<5, Anti Mullerian Hormone (AMH)<1 and previous trial <5 oocyte retrieved)

• Severe male factor, uterine abnormalities, adenomyosis and endometriosis

• History of malignant tumors and related treatment, clinically significant systemic disease or abnormal hematology, chemistry, or urinalysis results at screening, non-ovarian causes (male or tubal factors with average ovarian reserve).